(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
2 September 2010 (02.09.2010)

PCT

(10) International Publication Number
WO 2010/099458 A1

(51) International Patent Classification:
A61K 31/4709 (2006.01) *A61P 31/14* (2006.01)
A61K 31/7068 (2006.01) *A61P 1/16* (2006.01)

(21) International Application Number:
PCT/US2010/025611

(22) International Filing Date:
26 February 2010 (26.02.2010)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/156,414 27 February 2009 (27.02.2009) US
61/257,367 2 November 2009 (02.11.2009) US

(71) Applicants *(for all designated States except US)*: **INTERMUNE, INC.** [US/US]; 3280 Bayshore Boulevard, Brisbane, CA 94005 (US). **ROCHE PALO ALTO LLC** [US/US]; 3431 Hillview Ave., Palo Alto, CA 94304 (US). **PHARMASSET, INC.** [US/US]; 303-A College Road East, Princeton, NJ 08540 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **PORTER, Steven, B.** [US/US]; 64 Mountain View Avenue, Mill Valley, CA 94941 (US). **BRADFORD, Williamson, Ziegler** [US/US]; P.O. Box 566, Ross, CA 94957 (US). **SMITH, Patrick, F.** [US/US]; 2675 Calle Morcelia, Pleasanton, CA 94566 (US). **YETZER, Ellen, S.** [US/US]; 2140 Pacific Avenue #104, San Francisco, CA 94115 (US). **DE LA ROSA, Abel** [US/US]; 6850 Ridgefield Drive, Alpharetta, GA 30005 (US). **ROGERS, Michael, D.** [US/US]; 101 Ellsworth Place, Chapel Hill, NC 27516 (US). **SYMONDS, William, T.** [US/US]; 103 Hardenbrook Court, Cary, NC 27519 (US).

(74) Agent: **MALLON, Joseph, J.**; Knobbe Martens Olson & Bear LLP, 2040 Main Street, 14th Floor, Irvine, CA 92614 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMBINATION OF A NUCLEOSIDE POLYMERASE INHIBITOR WITH A MACROCYCLIC PROTEASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF HEPATITIS C, LIVER FIBROSIS AND IMPAIRED LIVER FUNCTION




FIG. 4

(57) Abstract: Embodiments disclosed in the present application relate to a composition that can include a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof. Additional embodiments disclosed relate to methods for treating a disease condition such as a hepatitis C virus infection, liver fibrosis and/or impaired liver function with a hepatitis C viral polymerase inhibitor, or pharmaceutically acceptable salt or prodrug thereof and a hepatitis C viral protease inhibitor, or pharmaceutically acceptable salt or prodrug thereof.

WO 2010/099458 A1

Published:

— *with international search report (Art. 21(3))*